Dmitry Balyasny’s Corvus Pharmaceuticals CRVS Stock Holding History

Dmitry Balyasny’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,031	Closed	-$193K	–	2983
2025 Q4	$193K	Sell	25,031 -541	-2%	-$4.27K	﹤0.01%	2891
2025 Q3	$188K	Buy	+25,572	New	+$131K	﹤0.01%	2736
2025 Q2	–	Sell	-57,827	Closed	-$184K	–	2904
2025 Q1	$184K	Buy	57,827 +9,492	+20%	+$44.7K	﹤0.01%	2606
2024 Q4	$259K	Buy	+48,335	New	+$361K	﹤0.01%	2451

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dmitry Balyasny's CRVS Position: Q1 2026 in Review

Dmitry Balyasny sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 25,031 shares — an estimated $193K sold.

Dmitry Balyasny first reported a position in CRVS in Q4 2024 and held it in 4 quarters. The position peaked at $259K in Q4 2024. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

Dmitry Balyasny reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Dmitry Balyasny sold 25,031 Corvus Pharmaceuticals shares in Q1 2026, an estimated $193K.
Dmitry Balyasny first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Dmitry Balyasny's Corvus Pharmaceuticals position peaked at $259K in Q4 2024.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.